Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional)

Nov. 26, 2025, 12:00 a.m. EST

Sept. 25, 2028, 12:00 a.m. EDT Due in 974 Days

Jan. 5, 2026, 11:48 a.m. EST

2

Oct. 30, 2028

City or township governments
Native American tribal organizations (other than Federally recognized tribal governments)
Public and State controlled institutions of higher education
Special district governments
Native American tribal governments (Federally recognized)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
State governments
Others (see text field entitled "Additional Information on Eligibility" for clarification)
Independent school districts
For profit organizations other than small businesses
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Small businesses
Private institutions of higher education
County governments

Specific to this NOFO:For New (Type 1) applications, an applicant institution must have a funding base of $10,000,000 (Clinical Cancer Centers) or $6,000,000 (Basic Cancer Centers) in annual direct costs of NIH funding that is cancer-focused, as defined by the Research Condition and Disease Categorization (RCDC) system. Please contact the NCI Office of Cancer Centers (https://cancercenters.cancer.gov/) for assistance in determining the RCDC funding base.For Renewal (Type 2) applications, an applicant institution must have a funding base of at least $10,000,000 in annual direct costs of peer-reviewed, cancer-related funding. If the Cancer Center is an approved consortium of institutions, the funding base of the Center will be the sum of the funding bases of all participating institutions. However, funding (and other data) awarded to consortium partners may be included only if the partner has been previously evaluated in CCSG peer-review and approved by NCI.Example of NCI peer-reviewed mechanisms that may be included for determining eligibility to apply for a CCSG: DP1, DP2, R00, R01, R03, R15, R18, R21, R24, R25, R33, R35, R37, R41, R42, R50, R55, R56, P01, P20, P30s other than the CCSG, P50, SC1, SC2, U01, U10, U19, U24, U54, U56, UH2, UH3, UG3, T32, K and F series awards and N01s (excluding SEER and other N01s funding materials, services, or research resources). Cancer-relevant research funded by these mechanisms from other NIH Institutes may also be counted towards the minimum, as do cancer-relevant grants and contracts from the peer-reviewed funding sources listed in: https://cancercenters.cancer.gov/sites/default/files/PeerReviewFundingOrganizations.pdfNOTE: New (Type 1) applications cannot request evaluation for comprehensiveness status.Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organization) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

National Institutes of Health

ncicenters-r@mail.nih.gov

(301) 402-2541